ZYNE - Marijuana as medicine: the other cannabinoid pharma players

On Wednesday, Jazz Pharmaceuticals (JAZZ) said it would acquire GW Pharma (GWPH) in a $7.2B deal.Acquisition gives Jazz access to GW's cannibinoid drug for seizures, Epidiolex, as well as other cannibinoid-based therapies in the pipeline.Several other biopharmas are exploring cannibinoid treatments, including Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), and Zynerba Pharmaceuticals (ZYNE).Cara's CR-701 is a synthetic cannabinoid receptor agonist under pre-clinical investigation for neuropathic pain, in particular, hyperalgesia and allodynia.Corbus has Lenabasum, a cannabinoid receptor type 2 agonist, in phase 3 for systemic sclerosis and dermatomyositis.Zynerba's lead candidate is Zygel, a gel containing CBD (made in a lab), under evaluation in phase 2 for Fragile X syndrome, autism spectrum disorder in children, 22q, a group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.Pharma giant Abbvie (ABBV) is also engaged in cannabis-oriented therapies with its drug Marinol, also known as dronabinol, a synthetic version of THC, a cannabinoid

For further details see:

Marijuana as medicine: the other cannabinoid pharma players